AIGH Capital Management’s Grace Therapeutics GRCE Stock Holding History

AIGH Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-907,217	Closed	-$3.15M	–	51
2025 Q4	$3.15M	Hold	907,217	–	–	0.76%	27
2025 Q3	$2.7M	Sell	907,217 -221,280	-20%	-$694K	0.76%	31
2025 Q2	$3.35M	Sell	1,128,497 -193,882	-15%	-$516K	1.51%	23
2025 Q1	$3.02M	Buy	1,322,379 +801,296	+154%	+$2.52M	1.25%	26
2024 Q4	$1.96M	Sell	521,083 -120,000	-19%	-$411K	0.61%	26
2024 Q3	$1.93M	Hold	641,083	–	–	0.54%	27
2024 Q2	$1.88M	Buy	641,083 +143,724	+29%	+$433K	0.59%	27
2024 Q1	$1.71M	Buy	+497,359	New	+$1.47M	0.51%	33

Other funds holding GRCE

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

AIGH Capital Management's GRCE Position: Q1 2026 in Review

AIGH Capital Management sold out of Grace Therapeutics (GRCE) in Q1 2026, closing a stake of 907,217 shares — an estimated $3.15M sold.

AIGH Capital Management first reported a position in GRCE in Q1 2024 and held it in 8 quarters. The position peaked at $3.35M in Q2 2025. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

AIGH Capital Management reported no remaining Grace Therapeutics position as of Q1 2026 after selling out during the quarter.
AIGH Capital Management sold 907,217 Grace Therapeutics shares in Q1 2026, an estimated $3.15M.
AIGH Capital Management first reported a position in Grace Therapeutics in Q1 2024 and held it in 8 quarters.
AIGH Capital Management's Grace Therapeutics position peaked at $3.35M in Q2 2025.
34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on AIGH Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.